SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease.
glucagon-like peptide 1 receptor agonists
insulin resistance
metabolic dysfunction-associated fatty liver disease
sodium–glucose cotransporter 2 inhibitors
Journal
Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
11
11
2021
revised:
22
02
2022
accepted:
11
03
2022
pubmed:
2
5
2022
medline:
18
5
2022
entrez:
1
5
2022
Statut:
ppublish
Résumé
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition that affects nearly one billion people globally, characterized by triacylglycerol accumulation in the liver as a consequence of metabolic abnormalities (obesity and impaired glucose regulation). Low-grade inflammation, oxidative stress, mitochondrial dysfunction, and dysbiosis in gut microbiota are involved in the etiology of MAFLD, and both cardiovascular events and hepatic complications are the long-term consequences. In the absence of approved therapies for this condition, sodium-glucose cotransporter 2 inhibitors (SGLT-2 Is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have the specific advantage of lowering body weight and providing cardiovascular benefits. Here, we discuss potential roles for SGLT-2 Is and GLP-1 RAs in the prevention and treatment of intrahepatic triacylglycerol accumulation and associated inflammation and/or fibrosis.
Identifiants
pubmed: 35491295
pii: S1043-2760(22)00057-1
doi: 10.1016/j.tem.2022.03.005
pii:
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Triglycerides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
424-442Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.S.M. has been a member of advisory boards, or has consulted, for Novartis. He has received grant support from Handok. He has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, CKD Pharmaceutical, Dong-A ST, Eli Lilly & Co., Handok, HK InnoN, NovoNordisk, Sanofi, Takeda, and Yuhan. J.H.H. has been a member of advisory boards, or has consulted, for Merck. He has received grant support from CKD Pharmaceutical. He also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co, Merck, CKD, Hanmi Pharmaceutical, and NovoNordisk. Y.J.J. has nothing to disclose. E.F. serves on the advisory board of Boehringer Ingelheim/Eli Lilly & Co. and Lexicon, has grant support from J&J, Boehringer Ingelheim/ Eli Lilly & Co., and AstraZeneca, and has received speaker fees from Boehringer Ingelheim/ Eli Lilly & Co. M.A.N. has been a member of advisory boards, or has consulted, for AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Fractyl, GlaxoSmithKline, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and NovoNordisk. He has received grant support from AstraZeneca, Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma, and NovoNordisk. He has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, NovoNordisk, and Sun Pharma. S.L. has been a member of advisory boards, or has consulted, for Merck, Sharp & Dohme, and NovoNordisk. He has received grant support from AstraZeneca, Merck, Sharp & Dohme, and Astellas. He has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Merck, Sharp & Dohme, CKD Pharmaceutical, and NovoNordisk.